CAMBRIDGE, Mass.--(BUSINESS WIRE)--Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines targeting the activation of mTORC1, today announced that pharmaceutical industry veteran David M. Madden, founder and principal with Narrow River Management, LP and chairman of the board of directors of Dicerna Pharmaceuticals, has joined the Navitor Board of Directors as an independent Director, and also that accomplished researcher Michael Hall, PhD, Professor at Biozentrum of the University of Basel (Switzerland) and the discoverer of the target of rapamycin (TOR) complexes, has joined the Navitor Scientific Advisory Board.
Help employers find you! Check out all the jobs and post your resume.
